Table 1.
| (a) Demographic and clinical characteristics of patients presenting within 60 days of COVID-19 vaccination | Patients with CNS inflammatory event, n = 38 |
|---|---|
| Age at symptom onset, median years (range) | 39 (20–82) |
| Female, n (%) | 23 (60.5) |
| Pre-existing immune-mediated disease, n (%) | |
| RRMS | 4 (10.5) |
| Retrospective MS relapse | 1 (2.6) |
| Overlap syndrome (RA/SLE) | 1 (2.6) |
| None | 32 (84.2) |
| Vaccine received, n (%) | |
| Pfizer-BioN-Tech | 26 (68.4) |
| Moderna | 10 (26.3) |
| Oxford-AstraZeneca | 1 (2.6) |
| Unknown | 1 (2.6) |
| Symptom onset following, n (%) | |
| First dose | 13 (34.2) |
| Second dose | 16 (42.1) |
| Third dose | 7 (18.4) |
| Fourth dose | 2 (5.3) |
| Time of symptom onset post-vaccine, median days (range) | 15 (0-55) |
| Presenting symptoms, n (%) | |
| Numbness | 25 (65.8) |
| Weakness | 19 (50.0) |
| Sphincter dysfunction | 8 (21.1) |
| Vision loss | 6 (15.8) |
| Ataxia | 6 (15.8) |
| Dysarthria | 5 (13.2) |
| Diplopia | 1 (2.6) |
| Aphasia | 1 (2.6) |
| Vertigo | 1 (2.6) |
| EDSS at symptom nadir, median (range) | 2.5 (0–7) |
| Clinical syndrome, n (%) | |
| Transverse myelitis | 24 (63.2) |
| Hemispheric | 7 (18.4) |
| Optic neuritis | 6 (15.8) |
| Brainstem | 4 (10.5) |
| Cerebellar | 3 (7.9) |
| Thalamic | 1 (2.6) |
| Multifocal presentation, n (%) | 6 (15.8) |
| (b) Demographic and clinical characteristics of patients presenting within 30 days of COVID-19 vaccination. | Patients with CNS inflammatory event, n = 24 |
| Age at symptom onset, median years (range) | 44 (20–82) |
| Female, n (%) | 15 (62.5) |
| Pre-existing immune-mediated disease, n (%) | |
| RRMS | 3 (12.5) |
| Retrospective MS relapse | 1 (4.2) |
| Overlap syndrome (RA/SLE) | 1 (4.2) |
| None | 19 (79.2) |
| Vaccine received, n (%) | |
| Pfizer-BioN-Tech | 16 (66.7) |
| Moderna | 6 (25.0) |
| (b) Demographic and clinical characteristics of patients presenting within 30 days of COVID-19 vaccination. | Patients with CNS inflammatory event, n = 24 |
| Oxford-AstraZeneca | 1 (4.2) |
| Unknown | 1 (4.2) |
| Symptom onset following, n (%) | |
| First dose | 11 (45.8) |
| Second dose | 9 (37.5) |
| Third dose | 4 (16.7) |
| Time of symptom onset post-vaccine, median days (range) | 7 (0–30) |
| Presenting symptoms, n (%) | |
| Numbness | 18 (75.0) |
| Weakness | 10 (41.7) |
| Sphincter dysfunction | 6 (25.0) |
| Vision loss | 4 (16.7) |
| Dysarthria | 4 (6.7) |
| Ataxia | 2 (8.3) |
| Vertigo | 1 (4.2) |
| EDSS at symptom nadir, median (range) | 2.5 (0–7) |
| Clinical syndrome, n (%) | |
| Transverse myelitis | 16 (66.7) |
| Hemispheric | 4 (16.7) |
| Optic neuritis | 4 (16.7) |
| Brainstem | 3 (12.5) |
| Cerebellar | 2 (8.3) |
| Multifocal presentation, n (%) | 4 (16.7) |
Abbreviations: CNS: central nervous system; RRMS: relapsing remitting multiple sclerosis; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; EDSS: expanded disability status scale.